2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2018
Updates in heart failure 30-day readmission prevention
Goldgrab D, Balakumaran K, Kim M, Tabtabai S. Updates in heart failure 30-day readmission prevention. Heart Failure Reviews 2018, 24: 177-187. PMID: 30488242, DOI: 10.1007/s10741-018-9754-4.Peer-Reviewed Original ResearchConceptsHospital Readmissions Reduction ProgramAffordable Care ActReduce health care costsReadmission ratesReduce short-term readmissionsReadmissions Reduction ProgramHF readmissionHealth care costsCare costsShort-term readmissionCare ActAdmission diagnosisPrevent heart failureReduction programsRemote hemodynamic monitoringReadmissionMedical therapyHeart failureHF patientsHemodynamic monitoringHospitalProgram
2017
Acoustic speech analysis of patients with decompensated heart failure: A pilot study
Murton O, Hillman R, Mehta D, Semigran M, Daher M, Cunningham T, Verkouw K, Tabtabai S, Steiner J, Dec G, Ausiello D. Acoustic speech analysis of patients with decompensated heart failure: A pilot study. The Journal Of The Acoustical Society Of America 2017, 142: el401-el407. PMID: 29092550, PMCID: PMC5724620, DOI: 10.1121/1.5007092.Peer-Reviewed Original ResearchConceptsHeart failureIntracardiac filling pressuresDecompensated heart failureSpeech analysisIndicators of HFAcoustic speech analysisSpeech breathing characteristicsDiuretic treatmentPeripheral edemaPilot studyFilling pressureCreaky voiceSpeech passagesPatientsMonitoring patientsSpeech respirationSpeechIncreasing fundamental frequencyEdemaSustained vowelsAcoustic measurements
2015
Assessing mitral regurgitation in the prediction of clinical outcome after cardiac resynchronization therapy
Upadhyay G, Chatterjee N, Kandala J, Friedman D, Park M, Tabtabai S, Hung J, Singh J. Assessing mitral regurgitation in the prediction of clinical outcome after cardiac resynchronization therapy. Heart Rhythm 2015, 12: 1201-1208. PMID: 25708879, DOI: 10.1016/j.hrthm.2015.02.022.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapyDegree of baseline MRMitral regurgitationBaseline MRMR improvementHF hospitalizationClinical outcomesSurface QRSHeart failureAssociated with lower HF hospitalizationsCohort study of patientsImproved ventricular geometryFollow-up echocardiographyPrediction of clinical outcomeReducing mitral regurgitationStudy of patientsAll-cause mortalityPrediction of HFWorsening MRMR severityMedian ageIschemic cardiomyopathyResynchronization therapyImproved survivalMR reduction